Johnson & Johnson: Liver Diseases trials

The registry lists 16 Liver Diseases studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 15Phase 2 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedNCT02262728Phase 2Results posted
• A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)CompletedNCT05112952Phase 1
• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult ParticipantsCompletedNCT04960124Phase 1
• A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795CompletedNCT04844450Phase 1
• A Study of JNJ-53718678 in Participants With Hepatic ImpairmentTerminatedNCT04332523Phase 1
• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379CompletedNCT04208399Phase 1
• A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989CompletedNCT04208386Phase 1
• A Study of Orally Administered Pimodivir in Adult Participants With Hepatic ImpairmentCompletedNCT03816631Phase 1
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of ErdafitinibTerminatedNCT03587363Phase 1
• A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered EsketamineCompletedNCT02611505Phase 1
• A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic FunctionCompletedNCT02524717Phase 1
• A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic FunctionCompletedNCT01863784Phase 1
• A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic ImpairmentCompletedNCT01767948Phase 1
• A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic FunctionCompletedNCT01516047Phase 1
• A Study of TMC207 in Patients With Moderately Impaired Hepatic FunctionCompletedNCT01012284Phase 1
• TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.CompletedNCT00736905Phase 1